Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer treatment

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

Precision paediatrics: Treating patients with CAR-T

Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...

Blue Latitude Health

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

- PMLiVE

Evotec spins off cancer tech into new Breakpoint company

Will challenge AstraZeneca and others in DNA damage response

- PMLiVE

Pfizer adds Array to cancer arsenal with $11bn acquisition

Successful R&D teams to join Pfizer oncology network

- PMLiVE

Pfizer poaches cancer R&D head Jeff Settleman from Calico

Company gaining momentum in oncology

- PMLiVE

Has Amgen cracked KRAS? First clinical data says maybe

Progess on cancer 'master switch'

- PMLiVE

Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

An inflection point for MET-inhibitor class

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links